Galenica is repositioning its subsidiary Bichsel towards home healthcare

Galenica AG, a Swiss pharmaceutical group, has announced that its subsidiary Bichsel will cease pharmaceutical production by the end of 2026, impacting up to 170 jobs. This decision stems from insufficient competitiveness despite efforts to improve profitability. The closure will allow Bichsel to focus on the rapidly growing home healthcare sector. Experts in clinical nutrition and pain management, combined with a digital care management platform, will support home healthcare services. The transition includes a social plan to support affected employees and ensure customer supply during the changeover. Galenica expects exceptional charges of CHF 35 million to 40 million, but anticipates an improvement in adjusted EBIT of CHF 3 million per year after 2026.